Abstract: The invention concerns methods and constructs for producing retroviral particles, in vitro, ex vivo or in vivo. It also concerns the use of said methods and constructs for transferring nucleic acids into cells. More particularly, the invention concerns a composition comprising the whole set of genetic elements required for constituting a retroviral particle, incorporated in one or several recombinant adenoviruses defective for all or part of the regions E1 and E4 at least (adenoviral/retroviral chimeric vectors).
Type:
Grant
Filed:
January 25, 2001
Date of Patent:
December 3, 2002
Assignees:
Aventis Pharma S.A., Genopoietic
Inventors:
Christophe Torrent, Patrice Yeh, Michel Perricaudet, David Klatzmann, Jean-Loup Salzmann